Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H15F3N4O3 |
Molecular Weight | 416.3533 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CN(C[C@]1([H])[C@H]2N)C3=NC4=C(C=C3F)C(=O)C(=CN4C5=CC=C(F)C=C5F)C(O)=O
InChI
InChIKey=WVPSKSLAZQPAKQ-CDMJZVDBSA-N
InChI=1S/C20H15F3N4O3/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24/h1-4,7,10-11,16H,5-6,24H2,(H,29,30)/t10-,11+,16+
Molecular Formula | C20H15F3N4O3 |
Molecular Weight | 416.3533 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00685https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da9b26bb-d2d7-4113-a0f9-c6c2280f4875#Clinical_PharmacologyCurator's Comment: Description was created based on several sources, including
https://www.drugs.com/dosage/trovan.html
Sources: http://www.drugbank.ca/drugs/DB00685https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da9b26bb-d2d7-4113-a0f9-c6c2280f4875#Clinical_Pharmacology
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/dosage/trovan.html
Alatrofloxacin is a fluoroquinolone antibiotic developed as a mesylate salt and was sold under brand name Trovan, but was withdrawn from the U.S. market in 2001. Trovan was indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. After intravenous administration, alatrofloxacin is rapidly converted to trovafloxacin, which is responsible for therapeutic effect. Plasma concentrations of alatrofloxacin are below quantifiable levels within 5 to 10 minutes of completion of a 1 hour infusion.
CNS Activity
Originator
Sources: http://adisinsight.springer.com/drugs/800001875
Curator's Comment: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL364 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12878530 |
|||
Target ID: CHEMBL347 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11892894 |
|||
Target ID: CHEMBL614429 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11892894 |
|||
Target ID: CHEMBL352 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20407243 |
|||
Target ID: CHEMBL354 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11418510 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | TROVAN PRESERVATIVE FREE Approved UseTrovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date1997 |
|||
Sources: https://www.drugs.com/pro/trovan.html |
Curative | TROVAN Approved UseNosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated.
Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae.
Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species.
Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis.
Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. Launch Date1997 |
||
Curative | TROVAN Approved UseNosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated.
Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae.
Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species.
Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis.
Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. Launch Date1997 |
|||
Curative | TROVAN Approved UseNosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated.
Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae.
Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species.
Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis.
Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. Launch Date1997 |
|||
Curative | TROVAN PRESERVATIVE FREE Approved UseTrovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date1997 |
|||
Curative | TROVAN PRESERVATIVE FREE Approved UseTrovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date1997 |
|||
Curative | TROVAN PRESERVATIVE FREE Approved UseTrovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date1997 |
|||
Curative | TROVAN PRESERVATIVE FREE Approved UseTrovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date1997 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.9 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9935250 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.8 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
26.2 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
34.6 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
9.4 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
32.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9935250 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
12.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
9.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
13.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9935250 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
22% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
25.6% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
28.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
20.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1000 mg single, oral Highest studied dose |
healthy, 27 years n = 4 Health Status: healthy Age Group: 27 years Sex: M Population Size: 4 Sources: |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (4 patients) Sources: Vomiting (1 patient) Lightheadedness (4 patients) |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 881 Health Status: unhealthy Condition: chronic bronchitis or pneumonia Age Group: adult Sex: M+F Population Size: 881 Sources: |
Disc. AE: Gastrointestinal disorder NOS, CNS disorder (NOS)... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder NOS (11 patient) Sources: CNS disorder (NOS) (4 patients) Dizziness (2 patients) Dermatitis (2 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vomiting | 1 patient | 1000 mg single, oral Highest studied dose |
healthy, 27 years n = 4 Health Status: healthy Age Group: 27 years Sex: M Population Size: 4 Sources: |
Lightheadedness | 4 patients | 1000 mg single, oral Highest studied dose |
healthy, 27 years n = 4 Health Status: healthy Age Group: 27 years Sex: M Population Size: 4 Sources: |
Nausea | 4 patients | 1000 mg single, oral Highest studied dose |
healthy, 27 years n = 4 Health Status: healthy Age Group: 27 years Sex: M Population Size: 4 Sources: |
Gastrointestinal disorder NOS | 11 patient Disc. AE |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 881 Health Status: unhealthy Condition: chronic bronchitis or pneumonia Age Group: adult Sex: M+F Population Size: 881 Sources: |
Dermatitis | 2 patients Disc. AE |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 881 Health Status: unhealthy Condition: chronic bronchitis or pneumonia Age Group: adult Sex: M+F Population Size: 881 Sources: |
Dizziness | 2 patients Disc. AE |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 881 Health Status: unhealthy Condition: chronic bronchitis or pneumonia Age Group: adult Sex: M+F Population Size: 881 Sources: |
CNS disorder (NOS) | 4 patients Disc. AE |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 881 Health Status: unhealthy Condition: chronic bronchitis or pneumonia Age Group: adult Sex: M+F Population Size: 881 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 4.0 |
yes | |||
Page: 4.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Anti-Toxoplasma gondii activities and structure-activity relationships of novel fluoroquinolones related to trovafloxacin. | 1999 Jul |
|
Trovafloxacin-induced weakness due to a demyelinating polyneuropathy. | 2000 May |
|
Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques. | 2000 Oct |
|
History of quinolones and their side effects. | 2001 |
|
Telithromycin. | 2001 |
|
Bactericidal assays for fluoroquinolones. | 2001 |
|
In vitro activity of fluoroquinolones (gatifloxacin, levofloxacin and trovafloxacin) and seven other antibiotics against Streptococcus pneumoniae. | 2001 Apr |
|
Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships. | 2001 Aug |
|
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii]. | 2001 Dec |
|
Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin. | 2001 Dec |
|
Peripheral neuropathy associated with fluoroquinolones. | 2001 Dec |
|
Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae. | 2001 Dec |
|
In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. | 2001 Dec |
|
Guidelines and critical pathways for severe hospital-acquired pneumonia. | 2001 Feb |
|
In vitro activity of new quinolones against Clostridium difficile. | 2001 Feb |
|
Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila. | 2001 Feb |
|
Antibiotic side effects. | 2001 Jan |
|
Nigerian government investigates Pfizer drug trial allegations. | 2001 Jan 13 |
|
Pfizer accused of testing new drug without ethical approval. | 2001 Jan 27 |
|
In vitro development of resistance to three quinolones in Streptococcus pneumoniae. | 2001 Jan-Feb |
|
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. | 2001 Jul |
|
Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents. | 2001 Jul |
|
Effects of low levels of ciprofloxacin on a chemostat model of the human colonic microflora. | 2001 Jun |
|
Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents. | 2001 Jun |
|
Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae. | 2001 Jun |
|
Determination of trovafloxacin in human serum by time resolved terbium-sensitised luminescence. | 2001 Jun |
|
Effects of fluoroquinolones on the locomotor activity in rats. | 2001 Mar |
|
Antimicrobial safety and tolerability: differences and dilemmas. | 2001 Mar 15 |
|
Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens. | 2001 May |
|
In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens. | 2001 May-Jun |
|
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. | 2001 Nov |
|
Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae independent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analyses. | 2001 Nov |
|
Seizures associated with fluoroquinolones. | 2001 Oct |
|
High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission. | 2001 Oct |
|
Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones. | 2001 Oct |
|
Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. | 2001 Sep |
|
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. | 2001 Sep |
|
Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. | 2001 Sep 15 |
|
In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media. | 2001 Sep-Oct |
|
Gatifloxacin: a review of its use in the management of bacterial infections. | 2002 |
|
A critical review of the fluoroquinolones: focus on respiratory infections. | 2002 |
|
Susceptibility of human isolates of Salmonella typhimurium DT 104 to antimicrobial agents used in human and veterinary medicine. | 2002 Jan |
|
Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. | 2002 Jan |
|
Bactericidal mechanism of gatifloxacin compared with other quinolones. | 2002 Jan |
|
Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates. | 2002 Mar |
|
Nigerians in drug trial take their case to US court. | 2003 Apr 26 |
|
Globalized clinical trials and informed consent. | 2009 May 14 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/trovan.html
Nosocomial Pneumonia - 300 mg I.V. followed by 200 mg oral, 10–14 days
Community Acquired Pneumonia - 200 mg oral or 200 mg I.V. followed by 200 mg oral, 7–14 days
Gynecologic and Pelvic Infections - 300 mg I.V. followed by 200 mg oral, 7–14 days
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11418510
Trovafloxacin inhibited Escherichia coli growth with MIC50 = 0.125mg/L
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:21:43 GMT 2023
by
admin
on
Fri Dec 15 16:21:43 GMT 2023
|
Record UNII |
9F388J00UK
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
J01MA13
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
||
|
WHO-VATC |
QJ01MA13
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
||
|
NCI_THESAURUS |
C795
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
||
|
LIVERTOX |
NBK547840
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID0041145
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
PRIMARY | |||
|
9F388J00UK
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
PRIMARY | |||
|
9763
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
PRIMARY | |||
|
147059-72-1
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
PRIMARY | |||
|
m11237
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB11350MIG
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
PRIMARY | |||
|
2777
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
PRIMARY | |||
|
7370
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
PRIMARY | |||
|
Trovafloxacin
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
PRIMARY | |||
|
100000089214
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
PRIMARY | |||
|
C080163
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
PRIMARY | |||
|
115552
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
PRIMARY | RxNorm | ||
|
Trovafloxacin
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
PRIMARY | |||
|
CHEMBL428
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
PRIMARY | |||
|
C66644
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
PRIMARY | |||
|
9F388J00UK
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
PRIMARY | |||
|
DB00685
Created by
admin on Fri Dec 15 16:21:43 GMT 2023 , Edited by admin on Fri Dec 15 16:21:43 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
18 STRAINS LESS THE 8 ng/mL for many strains; mic range listed
MIC90
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
EXCRETED UNCHANGED |
FECAL
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
EXCRETED UNCHANGED |
URINE
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|